A detailed history of Goldman Sachs Group Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 258,368 shares of KROS stock, worth $11.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
258,368
Previous 205,099 25.97%
Holding current value
$11.8 Million
Previous $8.15 Million 109.75%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$41.26 - $70.48 $2.2 Million - $3.75 Million
53,269 Added 25.97%
258,368 $17.1 Million
Q4 2023

Feb 13, 2024

BUY
$27.12 - $41.05 $2.85 Million - $4.31 Million
105,040 Added 104.98%
205,099 $8.15 Million
Q3 2023

May 14, 2024

SELL
$31.57 - $43.02 $3.32 Million - $4.52 Million
-105,040 Reduced 51.21%
100,059 $3.19 Million
Q3 2023

Nov 14, 2023

BUY
$31.57 - $43.02 $825,618 - $1.13 Million
26,152 Added 35.39%
100,059 $3.19 Million
Q2 2023

May 14, 2024

BUY
$37.26 - $51.01 $433,967 - $594,113
11,647 Added 18.71%
73,907 $2.97 Million
Q2 2023

Aug 14, 2023

BUY
$37.26 - $51.01 $433,967 - $594,113
11,647 Added 18.71%
73,907 $2.97 Million
Q1 2023

May 14, 2024

SELL
$41.44 - $59.32 $3.46 Million - $4.96 Million
-83,562 Reduced 57.3%
62,260 $2.66 Million
Q1 2023

May 11, 2023

SELL
$41.44 - $59.32 $3.46 Million - $4.96 Million
-83,562 Reduced 57.3%
62,260 $2.66 Million
Q4 2022

May 14, 2024

SELL
$39.45 - $51.77 $1.2 Million - $1.58 Million
-30,542 Reduced 17.32%
145,822 $7 Million
Q4 2022

Feb 13, 2023

SELL
$39.45 - $51.77 $1.2 Million - $1.58 Million
-30,542 Reduced 17.32%
145,822 $7 Million
Q3 2022

May 14, 2024

BUY
$27.8 - $40.12 $792,661 - $1.14 Million
28,513 Added 19.28%
176,364 $6.64 Million
Q3 2022

Nov 10, 2022

BUY
$27.8 - $40.12 $792,661 - $1.14 Million
28,513 Added 19.28%
176,364 $6.63 Million
Q2 2022

May 14, 2024

SELL
$26.03 - $67.04 $1.49 Million - $3.84 Million
-57,248 Reduced 27.91%
147,851 $4.09 Million
Q2 2022

Aug 15, 2022

BUY
$26.03 - $67.04 $521,120 - $1.34 Million
20,020 Added 15.66%
147,851 $4.09 Million
Q1 2022

May 16, 2022

BUY
$42.12 - $59.36 $359,409 - $506,518
8,533 Added 7.15%
127,831 $6.95 Million
Q4 2021

Feb 14, 2022

BUY
$36.95 - $62.89 $2.49 Million - $4.24 Million
67,389 Added 129.82%
119,298 $6.98 Million
Q3 2021

Nov 10, 2021

BUY
$29.27 - $43.71 $1.52 Million - $2.27 Million
51,909 New
51,909 $2.05 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.18B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.